DSM Pharmaceutical Products Announces the Appointment of That's Nice LLC as Agency of Record for Marketing
Geschrieben am 10-09-2008 |
Parsippany, New Jersey (ots/PRNewswire) -
DSM Pharmaceutical Products (DPP) announced today the appointment of That's Nice LLC as agency of record for marketing services. This relationship, in effect since June 2008, covers services for this DSM business group and its three business units: DSM Pharma Chemicals, DSM Biologics and DSM Pharmaceuticals, Inc.
DSM Pharmaceutical Products offers custom manufacturing for pharmaceutical chemicals, manufacturing technology and services for biopharmaceuticals, and secondary manufacturing of both. Guy Tiene, director of marketing and communications for DSM Pharmaceutical Products, said, "This requires an integrated communications program and a wide range of marketing activities."
Kristine Senft, senior vice president of pharmaceutical chemicals at DSM said, "That's Nice has been in the industry for more than ten years with a solid reputation among many companies in pharmaceutical supply. We have already begun work on strategic marketing for DPP, beginning with an evolution in communications aligned to business objectives for the CPhI Worldwide 2008 trade show."
Nigel Walker, managing director of That's Nice LLC added "We are delighted to have been selected as the agency for DSM Pharmaceutical Products. DPP's position in these markets, and the business units that uniquely cover such a spectrum of the market, make it a very appealing challenge that is completely aligned with our services."
About That's Nice LLC
That's Nice LLC, based in New York City, is a full service agency providing brand and marketing management with value added business support. It offers a comprehensive range of marketing services and specializes in integrated branding and marketing, web development services, and corporate gift and premium sourcing through its subsidiary, Nice Gift. That's Nice has served the Pharmaceutical Supply, Fine Chemicals and Life Sciences markets since 1997. For more information, please visit www.thatsnice.com.
About DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM Pharmaceutical Products contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active ingredients (API's), fermentation, mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticals.com
DSM - the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com.
DSM Forward-looking statements
Any forward-looking statements contained in this press release that involve inherent risks and uncertainties are based on current expectations, estimates and projections of the management of DSM and information currently available. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update any statements contained in this press release.
For further information please contact: DSM Pharmaceutical Products That's Nice LLC Guy Tiene Nigel Walker Director, Marketing & Managing Director Communications That's Nice LLC DSM Pharmaceutical Products Tel: +1-212-366-4455 Tel: +1-973-257-8160 nigel@thatsnice.com guy.tiene@dsm.com Web site: http://www.thatsnice.com http://www.dsmpharmaceuticals.com http://www.dsm.com
ots Originaltext: That's Nice LLC; DSM Pharmaceutical Products Im Internet recherchierbar: http://www.presseportal.de
Contact: Guy Tiene Director, Marketing & Communications of DSM Pharmaceutical Products, +1-973-257-8160, guy.tiene@dsm.com; or Nigel Walker, Managing Director of That's Nice LLC, +1-212-366-4455, nigel@thatsnice.com
Kontaktinformationen:
Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.
Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.
Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.
http://www.bankkaufmann.com/topics.html
Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.
@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf
E-Mail: media(at)at-symbol.de
157803
weitere Artikel:
- Cavotec MSL Group vertraut Verizon Business seine globale Kommunikation an Reading, England (ots/PRNewswire) - - Wechsel zu IP-Telefonie mit Lösungen von Verizon Business Die Cavotec MSL Group, weltweit führend bei Energieversorgungslösungen, strebt den Wechsel zu einem IP-basierten Kommunikationsumfeld an und hat deshalb seine globale Kommunikations-Infrastruktur Verizon Business anvertraut. Eine komplett gemanagte Verizon Private IP-Lösung wird in diesem Zusammenhang für sichere und schnelle Konnektivität zwischen den betrieblichen Einrichtungen von Cavotec MSL rund um die Welt sorgen. Weiter dient sie mehr...
- GlaxoSmithKline and Cellzome Announce Major Strategic Alliance LONDON and CAMBRIDGE, England and PHILADELPHIA and HEIDELBERG, Germany, September 10 (ots/PRNewswire) -- - Kinobeads(TM) Technology to Identify a New Generation of Drug Candidates for Inflammatory Diseases Cellzome Inc. and GlaxoSmithKline (LSE & NYSE: GSK) announce the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases. The alliance gives GSK access to Cellzome's significant expertise in identifying and developing selective kinase inhibitors mehr...
- euro adhoc: DZ BANK AG / Sonstige Kapitalmarkinformation gemäß § 30e WpHG -------------------------------------------------------------------------------- Sonstige Kapitalmarktinformationen gemäß § 30 e WpHG übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- 10.09.2008 Anleihe: EUR 75.000.000 5,100% Inhaber-Teilschuldverschreibungen von 2008/2009; 1. Aufstockung: von EUR 25.000.000 um EUR 75.000.000 auf EUR 100.000.000 ISIN: DE000DZ1HAJ9; Emission: 4973; Valuta: mehr...
- Norwegische Anleihen bieten attraktive Renditen Frankfurt am Main (ots) - - Zyklischer Höhepunkt des Leitzinses trotz Inflationsdruck bereits erreicht - Mittelfristig Annäherung an europäisches Zinsniveau zu erwarten - Vermehrt Anzeichen für Aufwertung der Norwegische Krone erkennbar Der Ölpreisboom der vergangenen Monate hat die wirtschaftliche Entwicklung vieler Länder gebremst. Nicht so in Norwegen: Dort kam es in der Folge sogar zu einer konjunkturellen Überhitzung, die - verglichen mit dem übrigen Europa - einen deutlich höheren Inflationsdruck hervorrief. mehr...
- euro adhoc: DZ BANK AG / Sonstige Kapitalmarkinformation gemäß § 30e WpHG -------------------------------------------------------------------------------- Sonstige Kapitalmarktinformationen gemäß § 30 e WpHG übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- 10.09.2008 Anleihe: EUR 50.000.000 4,85% Inhaber-Teilschuldverschreibungen von 2008/2008; 4. Aufstockung: von EUR 200.000.000 um EUR 50.000.000 auf EUR 250.000.000 ISIN: DE000DZ1G747; Emission: 4858; Valuta: mehr...
|
|
|
Mehr zu dem Thema Finanzen
Der meistgelesene Artikel zu dem Thema:
Century Casinos wurde in Russell 2000 Index aufgenommen
durchschnittliche Punktzahl: 0 Stimmen: 0
|